Cora N. Sternberg

TL;DR: This secondary analysis of the PREVAIL and AFFIRM randomized clinical trials found that chemotherapy-naive men with new early bone lesions whose condition was stable or responding to enzalutamide had similar progression-free and overall survival times and a quality of life similar to that of men without new lesions whosecondition was responding to enzymes.

TL;DR: Results from the phase 3 KEYNOTE-045 study comparing pembro and investigator’s choice of chemotherapy (chemo) study suggest pemBro was approved for the treatment of breast cancer by the US Food and Drug Administration (FDA) in May 2013.

TL;DR: The largest ever study of its kind has been conducted on the role of language and culture in the development of Alzheimer's disease and its effects on physical and mental health.

TL;DR: This real-world study shows that not all patients with mCRPC received a life-prolonging therapy, and their back-to-back use was common despite reported cross-resistance and limited benefit.

TL;DR: It is illustrated that at least two agents—menogarol and 4′-epirubicin—may have some antitumor activity against pancreatic carcinoma in this system.